Welcome to our dedicated page for Sarepta Therapeutics SEC filings (Ticker: SRPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sarepta Therapeutics, Inc. (SRPT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Sarepta is a biotechnology issuer listed on the NASDAQ Global Select Market, and its filings offer detailed insight into its precision genetic medicine business, capital structure and risk profile.
For investors analyzing SRPT, Forms 10-K and 10-Q (when available) describe Sarepta’s focus on rare diseases, including Duchenne muscular dystrophy, and its portfolio of RNA-targeted and gene transfer therapies. These periodic reports typically discuss marketed products such as ELEVIDYS and PMO exon-skipping therapies, outline research and development priorities across muscle, central nervous system and cardiac diseases, and present management’s view of key risks and uncertainties.
Current reports on Form 8-K are particularly relevant for Sarepta, as they document material events such as exchange transactions involving its 1.25% Convertible Senior Notes due 2027 and new 4.875% Convertible Senior Notes due 2030, private placements of common stock, strategic restructuring actions and executive transitions. These filings also reference press releases that announce quarterly financial results, clinical trial milestones, FDA decisions on ELEVIDYS labeling, and clinical holds affecting certain limb girdle muscular dystrophy gene therapy programs.
Users interested in capital markets activity and potential dilution can review disclosures about unregistered sales of equity securities, convertible note terms, and related exchange agreements. Over time, proxy statements and other governance-related filings can provide additional detail on board structure and compensation policies.
Stock Titan enhances these SRPT filings with AI-powered summaries that explain complex sections in plain language, highlight key changes from prior periods and surface items such as revenue drivers, pipeline updates and financing terms. Real-time updates from EDGAR, along with structured access to Form 4 insider transaction reports when filed, help investors monitor how Sarepta’s regulatory disclosures evolve as its genetic medicine programs progress.
Sarepta Therapeutics Inc is reported as having 5,369,116 shares beneficially owned by Vanguard Capital Management, representing 5.11% of the common stock. The filing states Vanguard has sole voting power for 790,881 shares and sole dispositive power for 5,369,116 shares. The disclosure attributes ownership across Vanguard affiliates as described in the filing.
Sarepta Therapeutics: Vanguard Portfolio Management reports ownership of 6,751,168 shares of Common Stock, representing 6.43% of the class. The filing states Vanguard has sole dispositive power over 6,751,168 shares and sole voting power over 110,476 shares. The statement is signed by Ashley Grim on 04/29/2026.
Sarepta Therapeutics is asking stockholders to vote at its June 4, 2026 virtual annual meeting on five key items. Investors are asked to elect five Class I directors to serve until 2028, approve on an advisory basis 2025 executive pay, and ratify KPMG LLP as auditor for 2026.
The company also seeks approval of a new 2026 Equity Incentive Plan covering 6,740,000 shares and a 2026 Employee Stock Purchase Plan covering 1,500,000 shares. The proxy links these equity programs to retaining and motivating key talent during a planned CEO transition, as the current chief executive intends to retire by the end of 2026 or upon appointment of a successor.
Sarepta Therapeutics Inc ownership filing shows that The Vanguard Group reports 0 shares beneficially owned of Common Stock, representing 0% of the class. The filing notes an internal realignment effective January 12, 2026, under SEC Release No. 34-39538, causing certain Vanguard subsidiaries to report separately.
Sarepta Therapeutics, Inc. Chief Operating Officer Ian Michael Estepan reported a routine tax-related share disposition. On March 11, he had 1,097 shares of common stock withheld by the company at $17.03 per share to cover tax obligations tied to vesting of restricted stock units granted on March 10, 2025. After this withholding, he directly held 201,983 shares of Sarepta common stock, indicating he retains a substantial equity position in the company.
Sarepta Therapeutics, Inc. Chief Financial Officer Ryan Ho-Yan Wong reported a small share disposition tied to tax withholding, not an open-market trade. On March 11, 256 shares of common stock were withheld by the company at $17.03 per share to cover taxes on restricted stock units that vested from a grant dated March 10, 2025.
After this tax-withholding event, Wong directly holds 135,064 shares of Sarepta common stock. Because the shares were withheld to satisfy tax obligations rather than sold in the market, this filing reflects a routine compensation-related adjustment rather than a discretionary purchase or sale.
Sarepta Therapeutics, Inc. executive Louise Rodino-Klapac, President of R&D and Tech Ops, had 948 shares of common stock withheld on March 11, 2026 to cover tax obligations linked to restricted stock units that vested from a grant dated March 10, 2025. The shares were valued at $17.03 each for this tax-withholding calculation. After this transaction, she directly holds 225,323 shares of common stock, indicating this was a small, routine adjustment related to equity compensation rather than an open-market trade.
Sarepta Therapeutics director Stephen Mayo reported an open-market sale of 7,239 shares of common stock at $17.02 per share. According to the footnote, this sale was made to generate cash to pay taxes arising from the vesting of restricted stock unit awards, indicating a tax-driven transaction rather than a discretionary portfolio move. After the sale, Mayo directly held 1,765 Sarepta shares.
Sarepta Therapeutics, Inc. executive Cristin Rothfuss, EVP and General Counsel, reported a routine tax-related share disposition. On March 11, 2026, the company withheld 974 shares of common stock at $17.03 per share to satisfy tax obligations from restricted stock units that vested on March 10, 2025.
After this withholding, Rothfuss directly holds 137,544 shares of Sarepta common stock, so the transaction represents only a small portion of her overall position and does not reflect an open-market sale.